US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Defiance Autism Impact ETF

26.96

-0.2079-0.77%

Volume:200

Turnover:5.40K

Market Cap:1.35M

PE:- -

High:26.96

Open:26.96

Low:26.96

Close:27.17

52wk High:29.12

52wk Low:24.54

Shares:50.00K

Float Shares:50.00K

Volume Ratio:3.81

T/O Rate:0.40%

Dividend:0.01

Dividend Rate:0.02%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Press Release: MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Qianli Intelligent Driving's ASD System Surpasses 530,000 Installations, Integrated into 19 Models Including Smart

Neurotech raises $4.5m to fund pivotal ASD Phase III trial

Press Release: Oryzon Reports Financial Results and Corporate Update for Half Year Ended June 30th, 2026

MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia

SCIENTECH Shares Surge Over 18% in Morning Session Following Saudi Market Approval for Key Heart Devices

Neurotech taps $3.15m R&D tax loan to fund Phase III ASD trials

Neurotech Secures FDA IND Clearance for NTI164, Bolstering Global ASD Strategy

MapLight Announces Topline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum Disorder

Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control

NASDAQ TRADE HALT HALT NEWS PENDING AT 10:43 AM

Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis of Opioid Use in Patients with Fibromyalgia at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/stock/ASD/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"ASD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ASD\",,,,,undefined,":{"symbol":"ASD","market":"US","secType":"STK","nameCN":"Defiance Autism Impact ETF","latestPrice":26.96,"timestamp":1789061682544,"preClose":27.1679,"halted":0,"volume":200,"delay":0,"changeRate":-0.007652413326020732,"floatShares":50000,"shares":50000,"eps":0,"marketStatus":"Trading","change":-0.2079,"latestTime":"09-10 13:40:38 EDT","open":26.96,"high":26.96,"low":26.96,"amount":5395.311000000001,"amplitude":0,"askPrice":27.01,"askSize":200,"bidPrice":26.94,"bidSize":200,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1789070400000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":27.1679,"nav":27.31,"aum":1365500,"dividendRate":0.000221,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":27.335,"preClose":27.1679,"latestTime":"16:10 EDT","volume":6,"amount":163.0074,"timestamp":1788984604382,"change":0.1671,"changeRate":0.006151,"amplitude":0},"volumeRatio":3.808292},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ASD\",,,,,undefined,":{"symbol":"ASD","floatShares":50000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":3.808292,"shares":50000,"dividePrice":0.00597,"high":26.96,"amplitude":0,"preClose":27.1679,"low":26.96,"week52Low":24.54,"pbRate":"--","week52High":29.12,"institutionHeld":0,"latestPrice":26.96,"eps":0,"divideRate":0.000221,"volume":200,"delay":0,"ttmEps":0,"open":26.96,"prevYearClose":29.12,"prevWeekClose":27.7374,"prevMonthClose":27.6173,"prevQuarterClose":26.76,"fiveDayClose":27.895,"twentyDayClose":27.7856,"sixtyDayClose":24.8631},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ASD\",params:#limit:5,,,undefined,":[{"date":"2026-06-24","symbol":"ASD","amount":0.00597,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-24","defaultRemindTime":1782307800000,"name":"Defiance Autism Impact ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-25","payableDate":"2026-06-24","currency":"USD","dateTimestamp":1782273600000,"payDate":"2026-06-25"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ASD\",market:\"US\",,,undefined,":[{"executeDate":"2026-06-24","recordDate":"2026-06-24","paymentDate":"2026-06-25","value":0.00597,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ASD\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ASD\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2659162663","title":"Press Release: MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162663","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162663?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651500,"startTime":"0","endTime":"0","summary":"trial of ML-007C-MA in adults with schizophrenia experiencing an acute. exacerbation of psychosis. The trial met its primary endpoint, with the. 210/3 mg twice-daily dose demonstrating a statistically significant and. clinically meaningful reduction in PANSS total score compared with. -- ML-007C-MA also demonstrated improvement on a prespecified. impairment and significant separation on key secondary endpoints,including CGI-S and the PANSS Marder positive factor.-- ML-007C-MA was generally well tolerated, with no serious or drug-related. severe adverse events and low rates of GI-related discontinuations. Its. clinical profile, including simple initiation, 99% of patients reaching","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASD","IE00BQXX3C00.GBP","LU1316542783.SGD","MA","LU0868494617.USD","LU2168564222.USD","IE00B1XK9C88.USD","ADP","LU0006306889.USD","UYG","XLF","IPAY","IE00BYQQ9H92.USD","LU1236620750.USD","IE00B775H168.HKD","BK4613","LU2764262908.HKD","FDFF","LU2417539215.USD","LU0174119429.USD","LU0965509010.AUD","IYG","STBQ","BK4559","LU2361044865.SGD","LU1718418525.SGD","IE000WAW04H5.SGD","LU0061474705.USD","LU0353189763.USD","BK4585","FNCL","LATR","LU1145028129.USD","MPLT","LU0672654240.SGD","LU2360107671.USD","LU0234570918.USD","LU2023250504.SGD","VFH","IE0005OL40V9.USD","LU0056508442.USD","LU1989764748.USD","LU2347655073.USD","LU1623119135.USD","LU0942090050.USD","LU2404859667.USD","LU1084165304.USD","IE00BJJMRX11.SGD","IE000F7OJYX1.SGD","LU2462157665.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136535851","title":"Qianli Intelligent Driving's ASD System Surpasses 530,000 Installations, Integrated into 19 Models Including Smart","url":"https://stock-news.laohu8.com/highlight/detail?id=1136535851","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136535851?lang=en_us&edition=fundamental","pubTime":"2026-08-08 16:20","pubTimestamp":1786177220,"startTime":"0","endTime":"0","summary":"Qianli Intelligent Driving has announced that its ASD 4.0 assisted driving system has been production-ready and launched in the new smart #1, following its earlier integration in the smart #6. This...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656886125","title":"Neurotech raises $4.5m to fund pivotal ASD Phase III trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2656886125","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656886125?lang=en_us&edition=fundamental","pubTime":"2026-08-04 07:38","pubTimestamp":1785800292,"startTime":"0","endTime":"0","summary":"An announcement from Neurotech International ( ($AU:NTI) ) is now available. Neurotech International has secured binding commitments for a $4.5 mil...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neurotech-raises-4-5m-to-fund-pivotal-asd-phase-iii-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neurotech-raises-4-5m-to-fund-pivotal-asd-phase-iii-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["III","BK4134","ASD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654704201","title":"Press Release: Oryzon Reports Financial Results and Corporate Update for Half Year Ended June 30th, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2654704201","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654704201?lang=en_us&edition=fundamental","pubTime":"2026-07-28 02:23","pubTimestamp":1785176580,"startTime":"0","endTime":"0","summary":"-- Positive clinical data presented at EHA for iadademstat in first line. in 100% ORR, 89% CRc and 78% CR, including in patients with TP53 or RAS. mutations; the triplet continued to demonstrate a favorable safety. gilteritinib continued to show a favorable safety profile and a high CRc. -- Enrollment initiated in Phase II trial of iadademstat in essential. -- U.S. patent granted for vafidemstat in borderline personality disorder. -- Cash position as of June 30, 2026 was $16.7 million ,excluding the gross proceeds of EUR12.0 million  raised in. -- On July 1, 2026, the company entered into a financing agreement with. COFIDES with a commitment to invest EUR25 million in future capital","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4144","SCD","BK4581","ORR","BK4161","ASD","ENFR","NCI","EIPI","BK4590","CR","BK4588","MDST","TNGY","UMI","AMZA","AMLP","BK4561","ET","MLPA","TPZ","BK4202","USAI","BK4585","EMLP","EIPX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654601468","title":"MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia","url":"https://stock-news.laohu8.com/highlight/detail?id=2654601468","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654601468?lang=en_us&edition=fundamental","pubTime":"2026-07-27 19:00","pubTimestamp":1785150000,"startTime":"0","endTime":"0","summary":"The trial, designed and sized to support registration, met its primary endpoint, with the 210/3 mg BID dose demonstrating a statistically significant improvement in PANSS total score compared to place","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/27/3333379/0/en/MapLight-Therapeutics-Announces-Positive-Topline-Results-from-Phase-2-ZEPHYR-Trial-of-ML-007C-MA-in-Schizophrenia.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2360107671.USD","UYG","LU0061475181.USD","LU1815333072.USD","LU0210533765.USD","LU0056508442.USD","IE00B4JS1V06.HKD","LU2506951958.HKD","LU0107464264.USD","MA","VFH","IYG","IPAY","LU1718418525.SGD","LU0823421333.USD","LU2168563687.JPY","MPLT","BK4533","LU1861217088.USD","IE000WAW04H5.SGD","FDFF","LU1983260115.SGD","LU0823434583.USD","BK4585","FNCL","LU0096362180.USD","LU1732800096.USD","BK4527","LU2168564149.EUR","LU0823417653.USD","SG9999003800.SGD","BK4139","LU1712237335.SGD","LU1280957306.USD","LU2077746001.SGD","LU0823421416.USD","BID","LU1316542783.SGD","LU0642271901.SGD","LU1868836914.USD","LU2092937148.SGD","IE00BKDWB100.SGD","LU0557290698.USD","LU2092627202.USD","ASD","LU2420271590.USD","XLF","STBQ","LATR","LU0708995401.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167544310","title":"SCIENTECH Shares Surge Over 18% in Morning Session Following Saudi Market Approval for Key Heart Devices","url":"https://stock-news.laohu8.com/highlight/detail?id=1167544310","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167544310?lang=en_us&edition=fundamental","pubTime":"2026-07-17 12:05","pubTimestamp":1784261101,"startTime":"0","endTime":"0","summary":"Shares of SCIENTECH (02291) surged more than 18% in the morning session.As of the latest update, the stock was up 16.49% to HK$13.07, with a trading turnover of approximately HK$50.09 million.The...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","02291","BK1100","VXUS","ASD","KCAI","IPOS","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651358324","title":"Neurotech taps $3.15m R&D tax loan to fund Phase III ASD trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2651358324","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651358324?lang=en_us&edition=fundamental","pubTime":"2026-07-15 10:27","pubTimestamp":1784082433,"startTime":"0","endTime":"0","summary":"Neurotech International ( ($AU:NTI) ) just unveiled an update. Neurotech International has secured a $3.15 million secured loan from Rockford RDF, ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neurotech-taps-3-15m-rd-tax-loan-to-fund-phase-iii-asd-trials?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neurotech-taps-3-15m-rd-tax-loan-to-fund-phase-iii-asd-trials?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ASD","III","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651147194","title":"Neurotech Secures FDA IND Clearance for NTI164, Bolstering Global ASD Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2651147194","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651147194?lang=en_us&edition=fundamental","pubTime":"2026-07-14 07:21","pubTimestamp":1783984875,"startTime":"0","endTime":"0","summary":"Neurotech International ( ($AU:NTI) ) has provided an update. Neurotech International has secured U.S. FDA clearance for its Investigational New Dr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neurotech-secures-fda-ind-clearance-for-nti164-bolstering-global-asd-strategy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neurotech-secures-fda-ind-clearance-for-nti164-bolstering-global-asd-strategy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LABU","ASD","BK4585","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645489021","title":"MapLight Announces Topline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2645489021","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645489021?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:00","pubTimestamp":1782126000,"startTime":"0","endTime":"0","summary":"The IRIS Phase 2 trial did not meet its primary endpoint in social communication deficits associated with ASD A prespecified analysis in adolescents with moderate to severe baseline irritability (ABC-","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/22/3315170/0/en/MapLight-Announces-Topline-Results-from-Phase-2-IRIS-Study-for-ML-004-in-Autism-Spectrum-Disorder.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065732104.USD","SPB","ASD","BK4018","ABI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643478322","title":"Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control","url":"https://stock-news.laohu8.com/highlight/detail?id=2643478322","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643478322?lang=en_us&edition=fundamental","pubTime":"2026-06-15 02:45","pubTimestamp":1781462700,"startTime":"0","endTime":"0","summary":"Data from up to two years of treatment in PATHFNDR-1 and PATHFNDR-2 open-label extension studies show PALSONIFY maintained lower IGF-1 levels and stable symptoms Treatment also resulted in stable or r","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/14/3311468/0/en/Crinetics-Presents-Long-Term-Data-at-ENDO-2026-Confirming-PALSONIFY-paltusotine-Provides-Durable-Consistent-Acromegaly-Control.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","ENDO","PTH","ASD","BK4196","BK4588","GH","BK4183","BK4585","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640950765","title":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 10:43 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2640950765","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640950765?lang=en_us&edition=fundamental","pubTime":"2026-06-01 22:43","pubTimestamp":1780324981,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 10:43 AM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nAQN2M1J9O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639619577","title":"Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis of Opioid Use in Patients with Fibromyalgia at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2639619577","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639619577?lang=en_us&edition=fundamental","pubTime":"2026-05-29 04:30","pubTimestamp":1780000200,"startTime":"0","endTime":"0","summary":"Real-world analysis of three years of closed claims data from Symphony Health, focused on the third year of the study (2023-2024), comprised of more than 261,000 U.S. adults with fibromyalgia Data dem","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/28/3303298/28908/en/Tonix-Pharmaceuticals-Presented-Retrospective-U-S-Real-World-Claims-Analysis-of-Opioid-Use-in-Patients-with-Fibromyalgia-at-the-2026-American-Society-of-Clinical-Psychopharmacology.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ASR","AUC","TNXP","LU0053687314.USD","BK4107","LU0029874061.USD","CNS","BK4135","LU0128526141.USD","LU2045819591.USD","BK4583","HI","LU2360032135.SGD","LU2125154935.USD","AFG","LU2125910500.SGD","BK4161","LU2125154778.USD","BK4117","LU0210535034.USD","BK4123","BK4174","ASD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":12,"code":"91000000","status":"200"}]}}